Coherus BioSciences (NASDAQ:CHRS – Get Free Report) is set to post its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Coherus BioSciences to post earnings of ($0.10) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to analyst estimates of $57.08 million. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Coherus BioSciences Price Performance
Shares of CHRS traded up $0.04 during midday trading on Tuesday, reaching $0.71. 1,156,660 shares of the stock were exchanged, compared to its average volume of 2,625,479. Coherus BioSciences has a twelve month low of $0.66 and a twelve month high of $3.73. The business’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.48. The company has a market capitalization of $81.81 million, a price-to-earnings ratio of -1.67 and a beta of 0.69.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Coherus BioSciences
About Coherus BioSciences
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Read More
- Five stocks we like better than Coherus BioSciences
- Stock Analyst Ratings and Canadian Analyst Ratings
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Insider Buying Signals Upside for These 3 Stocks
- ESG Stocks, What Investors Should Know
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.